Ad5-CD/TKrep gene therapy (Harvard Medical School)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameAd5-CD/TKrep gene therapy (Harvard Medical School)
Drug Alias Nameoncolytic adenovirus therapy expressing CD/HSV-1 TK fusion (Harvard Medical School)
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy > Viral vector-based gene therapy
Mechanisms of ActionThymidine kinase stimulants
TargetsThymidine kinase
Therapy Area/IndicationsProstatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHarvard Medical School
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHarvard Medical School
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A